​ HI. Index: 100

Publikationen : > 490 (05/2025)

​​Most important publications (Tschope C or Tschoepe C)

(Citations are directly linked with PubMed)

​​​

​​1. The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after SARS-CoV-2 infection and COVID-19 vaccination: Maatz H, Lindberg EL, Adami E, López-Anguita N, Perdomo-Sabogal A, Cocera Ortega L, Patone G, Reichart D, Myronova A, Schmidt S, Elsanhoury A, Klein O, Kühl U, ...,  Sander L, Sawitzki B, Klingel K, Doeblin P, Kelle S, Van Linthout S, Hubner N, Tschöpe C. Nat Cardiovasc Res. 2025 

​

2. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS. Mora-Ayestaran N, Dispenzieri A, Kristen AV, Maurer MS, Diemberger I, .......  Glass O, Amass L, Garcia-Pavia P;  ...Tschöpe C .....THAOS Investigators. JACC Adv. 2024

​

3. Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure. Alogna A, Berboth L, Faragli A, Ötvös J, Lo Muzio FP,  .......  Steendijk P, Mauri P, Tschöpe C, Borlaug B, Pieske BM, Attanasio P, Post H, Heinzel FR, Catalucci D. JACC 2024 

4.  Impact of cannabidiol on myocardial recovery in patients with acute myocarditis:  ARCHER trial. McNamara DM, Cooper LT, Arbel Y, Bhimaraj A, Bocchi E, Friedrich MG, Kerneis M, Liu P, Parker AB, Smith ER, Tang WHW, Torre-Amione G, Tschöpe C; ARCHER Study Group. ESC Heart Fail. 2024 

​

5. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Heymans S, ,,,,,,,Tschöpe C, Klingel K. Lancet. 2023 

​

​6. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. Polovina M, Tschöpe C, Rosano G, Metra M, Crea F, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Corrado D, Bayes-Genis A, Bozkurt B, Filippatos G, Keren A, Skouri H, Moura B, Volterrani M, Abdelhamid M, Ašanin M, Krljanac G, Tomić M, ...... , Seferović PM. Eur J Heart Fail. 2023 

​​​

​7. Cardiac fibroblasts and mechanosensation in heart development, health and disease. Pesce M, Duda GN, Forte G, Girao H, Raya A, Roca-Cusachs P, Sluijter JPG, Tschöpe C, Van Linthout S. Nat Rev Cardiol. 2022.

​​​​

8. IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. Thurner L, Kessel C, Fadle N, Regitz E, Seidel F, Kindermann I, Lohse S, Kos I, Tschöpe C, ...... et al . N Engl J Med. 2022.

​​

9. Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A Gyöngyösi M, Alcaide P, Asselbergs FW, Brundel BJJM, Camici GG, da Costa Martins P, Ferdinandy P, Fontana M, Girao H, Gnecchi M, Gollmann-Tepeköylü C, ....... , Pesce M, Schiattarella GG, Sluijter JPG, Steffens S, Tschöpe C .... et al. Cardiovasc Res. 2022

​​​

10. Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF). Linde C, Grabowski M, Ponikowski P, Rao I, Stagg A, Tschöpe C. Eur J Heart Fail. 2022 

​​​

11. Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, Future, and Challenges. Tschöpe C, Elsanhoury A. J Clin Med. 2022 

​​​

​​​12. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, et al Nat Rev Cardiol. 2021

​​​​

13. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, et al ; ESC Scientific Document Group. Eur Heart J. 2021 

​​​​

14. COVID-19 related cardiac complications - from clinical evidences to basic mechanisms. Opinion paper of the ESC Working Group on Cellular Biology of the Heart. Pesce M, Agostoni P, Bøtker HE, Brundel B, Davidson SM, De Caterina R, Ferdinandy P, Girao H, Gyöngyösi M, Hulot JS, Lecour S, Perrino C, Schulz R, Sluijter JPG, Steffens S, Tancevski I, Gollmann-Tepeköylü C, Tschöpe C  ..... et al Cardiovasc Res. 2021

15. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Seferović PM, Tsutsui H, Mcnamara DM, Ristić AD, Basso C, Bozkurt B, Cooper LT, Filippatos G, Ide T, Inomata T, Klingel K, Linhart A, Lyon AR, Mehra MR, Polovina M, Milinković I, Nakamura K, Anker SD, Veljić I, Ohtani T, Okumura T, Thum T, Tschöpe C et al J Card Fail. 2021

16 . The "TIDE"-Algorithm for the Weaning of Patients With Cardiogenic Shock and Temporarily Mechanical Left Ventricular Support With Impella Devices. A Cardiovascular Physiology-Based Approach. Tschöpe C, Spillmann F, Potapov E, et al. Front Cardiovasc Med. 2021

​​​​

17.    Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. Tschöpe C, Van Linthout S, Klein O, et al.  J Cardiovasc Transl Res. 2018

18. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Nat Commun. 2016

19.  Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschöpe C, et al. . N Engl J Med. 2015  
 
20. Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction.  Savvatis K, Pappritz K, Becher PM, Lindner D, Zietsch C, Volk HD, Westermann D, Schultheiss HP, Tschöpe C. Circ Heart Fail. 2014  
 
21. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Paulus WJ, Tschöpe C. J Am Coll Cardiol. 2013
 
22. Role of left ventricular stiffness in heart failure with normal ejection fraction. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschöpe C. Circulation. 2008